


## PD 119819

<b>Cat. No.:</b>	HY-118402
<b>CAS No.:</b>	105277-43-8
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>25</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	438.35
<b>Target:</b>	Dopamine Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis <sup>[1][2]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	Dopamine Receptor								
<b>In Vivo</b>	<p>PD 119819 (5~80 mg/kg; nasogastric intubation) makes monkeys show marked increases in alanine aminotransferase levels and a moderate increase in ornithine carbamyltransferase levels at the initial sampling interval after doses of 5 mg/kg with peak levels occurring after doses of 20 or 60 mg/kg, while lower values is evident after doses of 80 mg/kg<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Cynomolgus monkey<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>5~80 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Nasogastric intubation</td> </tr> <tr> <td>Result:</td> <td>Made monkeys show marked increases in alanine aminotransferase levels and a moderate increase in ornithine carbamyltransferase levels at the initial sampling interval after doses of 5 mg/kg with peak levels occurring after doses of 20 or 60 mg/kg, while lower values were evident after doses of 80 mg/kg.</td> </tr> </table>	Animal Model:	Cynomolgus monkey <sup>[1]</sup>	Dosage:	5~80 mg/kg	Administration:	Nasogastric intubation	Result:	Made monkeys show marked increases in alanine aminotransferase levels and a moderate increase in ornithine carbamyltransferase levels at the initial sampling interval after doses of 5 mg/kg with peak levels occurring after doses of 20 or 60 mg/kg, while lower values were evident after doses of 80 mg/kg.
Animal Model:	Cynomolgus monkey <sup>[1]</sup>								
Dosage:	5~80 mg/kg								
Administration:	Nasogastric intubation								
Result:	Made monkeys show marked increases in alanine aminotransferase levels and a moderate increase in ornithine carbamyltransferase levels at the initial sampling interval after doses of 5 mg/kg with peak levels occurring after doses of 20 or 60 mg/kg, while lower values were evident after doses of 80 mg/kg.								

### REFERENCES

- [1]. Macallum GE, et al. Renal and hepatic toxicity of a benzopyran-4-one in the Cynomolgus monkey. *Toxicology*. 1989;59(1):97-108.
- [2]. Jaen JC, et al. Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones. *J Med Chem*. 1991;34(1):248-256.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA